Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Ozanimod

被引：0
|
作者：
Zhang, Peijin [1 ]
Hosein, Fareeda [1 ]
Yu, Kyungha [1 ]
Walker, Susan [1 ]
Syto, Mary [1 ]
Tirucherai, Giridhar [1 ]
Murthy, Bindu [1 ]
Tatosian, Daniel [1 ]
机构：
[1] Bristol Myers Squibb, Princeton, NJ USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1532/314
引用
收藏
页码：976 / 976
页数：1
相关论文
共 50 条
  • [41] Pharmacokinetics of Maribavir in Subjects with Moderate Hepatic Impairment
    Song, I. H.
    Ilic, K.
    Wu, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 792 - 792
  • [42] The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase
    Khosravan, R
    Grabowski, BA
    Mayer, MD
    Wu, JT
    Joseph-Ridge, N
    Vernillet, L
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (01): : 88 - 102
  • [43] Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin
    Duchin, Kenneth
    Senaldi, Giorgio
    Warren, Vance
    Marbury, Thomas
    Lasseter, Kenneth
    Zahir, Hamim
    CLINICAL DRUG INVESTIGATION, 2018, 38 (11) : 1001 - 1009
  • [44] Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Oral Ivosidenib in Otherwise Healthy Participants
    Fan, Bin
    Dai, David
    Cohen, Marvin
    Xu, Huansheng
    Yin, Feng
    Nagaraja, Raj
    Mobilia, Michelle
    Almon, Caroline
    Basile, Frank G.
    Yang, Hua
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (01): : 99 - 109
  • [45] Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin
    Kenneth Duchin
    Giorgio Senaldi
    Vance Warren
    Thomas Marbury
    Kenneth Lasseter
    Hamim Zahir
    Clinical Drug Investigation, 2018, 38 : 1001 - 1009
  • [46] Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment
    John Marcinak
    Majid Vakilynejad
    Akifumi Kogame
    Yoshihiko Tagawa
    Drugs in R&D, 2018, 18 : 109 - 118
  • [47] Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
    Akifumi Kurata
    Takafumi Yoshida
    Megumi Inoue
    Tomoko Ishizuka
    Takafumi Nakatsu
    Takako Shimizu
    Manabu Kato
    Yasuhiro Nishikawa
    Hitoshi Ishizuka
    Advances in Therapy, 2020, 37 : 253 - 264
  • [48] Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
    Kurata, Akifumi
    Yoshida, Takafumi
    Inoue, Megumi
    Ishizuka, Tomoko
    Nakatsu, Takafumi
    Shimizu, Takako
    Kato, Manabu
    Nishikawa, Yasuhiro
    Ishizuka, Hitoshi
    ADVANCES IN THERAPY, 2020, 37 (01) : 253 - 264
  • [49] Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment
    Kulmatycki, Kenneth M.
    Langenickel, Thomas
    Ng, Wai Hong
    Pal, Parasar
    Zhou, Wei
    Lin, Tsu-Han
    Rajman, Iris
    Chandra, Priyamvada
    Sunkara, Gangadhar
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (09) : 728 - 739
  • [50] Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment
    Marcinak, John
    Vakilynejad, Majid
    Kogame, Akifumi
    Tagawa, Yoshihiko
    DRUGS IN R&D, 2018, 18 (02) : 109 - 118
12345